The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy
NCT ID: NCT03559647
Last Updated: 2023-09-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
358 participants
OBSERVATIONAL
2018-05-30
2023-08-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
NCT05047250
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NCT04984811
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
NCT04294810
A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC
NCT05991206
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
NCT04665856
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Participants who have demonstrated a lack of Clinical Benefit from Atezolizumab
No interventions assigned to this group
Cohort 2
Participants who demonstrated durability of Clinical Benefit and Tumor Response to Atezolizumab
Atezolizumab
Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
Atezolizumab will be administered per the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Decision to be treated with Atezolizumab according to Summary of Product Characteristics (SmPC) by treating physician, independent of this non-interventional study
* No contraindication to treatment with Atezolizumab
Retrospective Inclusion:
* Participants may be included retrospectively. Retrospective inclusion and documentation is limited to up to 9 weeks after initial start of therapy with Atezolizumab (corresponding to a maximum of 3 treatment cycles with drug administrations at 3-week intervals), corresponding to a maximum of 9 weeks prior to date of informed consent. Quality of life for this population will be captured and assessed retrospectively with a modified questionnaire for the period immediately prior to treatment start until study inclusion. participants who started Atezolizumab therapy more than 9 weeks prior to ICF being obtained may not be included in the study.
* Participants who give consent to be retrospectively enrolled but have already discontinued Atezolizumab for reasons such as loss of clinical benefit or toxicity may also take part in the study, given their first administration of Atezolizumab is within 9 weeks of consenting to take part, and they meet all other eligibility criteria.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg
Aschaffenburg, , Germany
Studienzentrum Aschaffenburg
Aschaffenburg, , Germany
Zentralklinikum Augsburg
Augsburg, , Germany
Dres. Helmut Tanzer Joachim Hornberger und Johannes Kern
Bad Reichenhall, , Germany
Klinikum Mittelbaden; Medizinisches Versorgungszentrum - Hämatologie und Onkologie
Baden-Baden, , Germany
Sozialstiftung Bamberg, Klinikum am Bruderwald, Gynäkologie
Bamberg, , Germany
St. Hedwig Kliniken Berlin GmbH
Berlin, , Germany
Onkologisches Versorgungszentrum Friedrichshain; Hämatologie, Onkologie und Palliativmedizin
Berlin, , Germany
Praxis Dr. Med. Gunhild Kühn
Berlin, , Germany
Onkologie am Segelfliegerdamm
Berlin, , Germany
Klinikum Bielefeld Mitte Klinik für Hämatologie, Onkologie u. Palliativmedizin
Bielefeld, , Germany
Onkologische Schwerpunktpraxis Bielefeld; Haemotologie & Internistische onkologie
Bielefeld, , Germany
Augusta Kranken-Anstalt gGmbH
Bochum, , Germany
Klinikum Koeln-Merheim; Lungenklinik
Cologne, , Germany
Fachkrankenhaus Coswig GmbH Zentrum f.Pneumologie Beatmungsmedizin Thorax-u.Gefäßchirurgie
Coswig, , Germany
Med. Versorgungszentrum Filiale Donauwörth Onkologisches Zentrum
Donauwörth, , Germany
Medizinische Klinik Nord, Lungenkrebszentrum
Dortmund, , Germany
BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie
Dresden, , Germany
Klinik St.Johannes-Hospital Medizinische Klinik I
Duisburg, , Germany
Klinikum Barnim GmbH; Med. Klinik I, Gastroenterologie, Hämatologie, Onkologie
Eberswalde, , Germany
Dres. Bruch, Buschmann, Linck
Euskirchen, , Germany
Hämatologisch-Onkologische Fachpraxis Dr. med. Th. Ehlers & Dr. med. N. Karapanagiotidis
Frankenthal/Pfalz, , Germany
Klinik Johann Wolfgang von Goethe Uni; Zentrum der Inneren Medizin; Medizinische Klinik I
Frankfurt, , Germany
St. Elisabethen Krankenhaus
Frankfurt am Main, , Germany
Klinikum Frankfurt Höchst GmbH; Klinik Innere Medizin 3 - Hämatologie, Onkologie, Palliativmedizin
Frankfurt am Main, , Germany
Dres.Jochen Wilke und Harald Wagner
Fürth, , Germany
Fachübergreifende Gemeinschaftspraxis Onkologie & Innere Medizin Dr. med. Haddadin & Panagiotou
Garbsen, , Germany
Niels-Stensen-Kliniken Franziskus-Hospital Harderberg GmbH
Georgsmarienhütte, , Germany
SRH Wald-Klinikum Gera; Zentrum fur klinische Studien (ZKS)
Gera, , Germany
Agaplesion Pneumologische Klinik Waldhof Elgershausen; Pneumologie
Greifenstein, , Germany
LungenClinic Großhansdorf GmbH
Großhansdorf, , Germany
Diakoniekrankenhaus Halle; Klinik für Pneumologie
Halle, , Germany
Praxis für Hämatologie und Onkologie in Hamburg
Hamburg, , Germany
OncoResearch Lerchenfeld GmbH
Hamburg, , Germany
Kath. Marienkrankenhaus gGmbH
Hamburg, , Germany
Hämatologische-Onkologische Schwerpunktpraxis
Hamburg, , Germany
Dres.Andreas Karcher und Stefan Fuxius
Heidelberg, , Germany
Onkologische Praxis in Heidenheim
Heidenheim, , Germany
Onkologische Schwerpunktpraxis Hof; Dres. Hanns-Detlev; Harich und Christian Kasper
Hof, , Germany
Klinikum Idar-Oberstein; Klinik für Neurochirurgie
Idar-Oberstein, , Germany
Klinikum Konstanz; MVZ Onkologie
Konstanz, , Germany
MVZ Hämatologie und Onkologie Krefeld
Krefeld, , Germany
Internistische Praxis Hämatologie und Onkologie
Kronach, , Germany
Klinikum Landshut Medizinische Klinik I
Landshut, , Germany
Gemeinschaftspraxis für Hämatologie und Onkologie, PD Dr. Bauer, Dr. Thiel
Lebach, , Germany
Dres. Barbara Tschechne Stefanie Luft und Wolf-Oliver Jordan
Lehrte, , Germany
Universität Leipzig; Medizinische Klinik und Poliklinik I, Abteilung Pneumologie
Leipzig, , Germany
ÜBAG MVZ Mitte / MVZ Delitzsch GmbH, Standort Leipzig
Leipzig, , Germany
Bonifatius Hospital Lingen gGmbH; Hämatologie und Onkologie
Lingen, , Germany
Lungenklinik Lostau
Lostau, , Germany
Klinikum Ludwigsburg; Studiensekretariat
Ludwigsburg, , Germany
Onkologische Schwerpunktpraxis Lübeck
Lübeck, , Germany
Klinikum Magdeburg gGmbH; Klinik für Hämatologie, Onkologie und Palliativmedizin
Magdeburg, , Germany
Gemeinschaftspraxis Fr. Dr. med. Balser & Hr. Dr. med. Weidenbach
Marburg, , Germany
Philipps-Universität Marburg; Klinik für Innere Med.; Schwerpunkt Hämatologie/Onkologie/Immunologie
Marburg, , Germany
Praxis für Innere Medizin und Pneumologie
Markkleeberg, , Germany
Dres. Michael Maasberg Marion Schmitz und Maria Theresia Keller
Mayen, , Germany
Joh. Wesling Klinikum Minden; Klinik fuer Hämatologie und Onkologie
Minden, , Germany
Gem.Praxis im Ärztezentrum Dr.med.Jörg Wiegand Jochen Eggert
Moers, , Germany
Kliniken Ostalb, Stauferklinikum Schwäbisch-Gmünd; Zentrum für Innere Medizin
Mutlangen, , Germany
Klinikum der Universität München; Medizinische Innenstadt
München, , Germany
Lungenklinik Münnerstadt, Thoraxzentrum Bezirk Unterfranken
Münnerstadt, , Germany
Gemeinschaftspraxis für Hämatologie und Onkologie
Münster, , Germany
Praxis Dr. Uhlig, Naunhof
Naunhof, , Germany
Friedrich-Ebert-Krankenhaus Klinik f. Hämatologie/ Onkologie u. Nephrologie
Neumünster, , Germany
Ruppiner Kliniken Medizinische Klinik A
Neuruppin, , Germany
Praxis Dr. Losem
Neuss, , Germany
Praxis für Hämatologie und Onkologie
Neuwied, , Germany
Klinikum Nuernberg Nord; Medizinische Klinik 3, Pneumologie, Oncologie
Nuremberg, , Germany
Pitri.Studien-GmbH (Ambulantes Therapiezentrum Hämatolgie/ Onkolgogie) Ärztehause 4 OG
Offenburg, , Germany
Sana Kliniken Ostholtstein; Klinik Oldenburg; Innere Medizin; Onkologie
Oldenburg, , Germany
Paracelsus-Klinik; Abteilung Haematologie und Onkologie
Osnabrück, , Germany
Onkologische Studien GbR, Dres. Becker, Kreisel-Büstgens und Moorahrend
Porta Westfalica, , Germany
Praxis für Hämatologie & Onkologie
Saarbrücken, , Germany
Schwerpunktpraxis für Hämatologie und Onkologie Dr. Med. Thomas Edelmann
Schkeuditz, , Germany
Zentrum Ambulante Onkologie
Schorndorf, , Germany
Zentrum für ambulante Hämatologie und Onkologie; Onkologische Praxis
Siegburg, , Germany
Onkologische Schwerpunktpraxis
Soest, , Germany
MVZ für Hämatologie, Onkologie, Strahlentherapie und Palliativmedizin -; Klinik Dr. Hancken
Stade, , Germany
Medizinisches Versorgungszentrum Stolberg
Stolberg, , Germany
Praxisnetzwerk Hämatologie und InternistischeIOnkologie
Troisdorf, , Germany
Universitätsklinikum Tübingen; Innere Medizin VIII, Medizinische Onkologie und Pneumologie
Tübingen, , Germany
Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo.
Ulm, , Germany
SHG-Kliniken Völklingen
Völklingen, , Germany
Regio Klinikum Wedel; Pneumologie
Wedel, , Germany
Praxis innere Medizin; Onkologie
Weimar, , Germany
MedFISMO ltd.
Weinsberg, , Germany
Gemeinschaftspraxis für Hämatologie und Onkologie Westerstede Aurich Rhauder
Westerstede, , Germany
Dres.Klaus Josten und Ortwin Klein
Wiesbaden, , Germany
Praxisgemeinschaft für Onkologie und Urologie, Wilhelmshaven
Wilhelmshaven, , Germany
Klinikverbund St. Antonius und St. Josef GmbH Petrus-Krankenhaus; Medi. Klinik III
Wuppertal, , Germany
MVZ West GmbH Wuerselen; Haematologie-Onkologie
Würselen, , Germany
Klinikum Würzburg Mitte gGmbH; Standort Missioklinik
Würzburg, , Germany
Praxis Dr.med. Mathias Schulze
Zittau, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML39885
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.